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Abstract
Epidemiologic studies indicate that bacterial vaginosis (BV), a common alteration of lower genital
tract flora in women, is associated with increased susceptibility to HIV infection. Other recent
studies show that HIV is detected more frequently and at higher levels in the lower genital tract of
HIV-seropositive women with BV. In vitro studies show that genital tract secretions from women
with BV or flora associated with BV induce HIV expression in infected cells. The increased HIV
expression appears to be due at least in part to activation through Toll-like receptors (TLR),
specifically TLR2. Further research is needed to elucidate how BV contributes to HIV acquisition
and transmission.
Review
Bacterial vaginosis
Bacteria colonize the lower genital tract of most women
and the predominant species of bacteria in healthy
women is lactobacilli. Commonly found vaginal lactoba-
cillus species include Lactobacillus crispatus, L. gasseri, L.
jensenii and L. iners [1,2]. Bacterial vaginosis (BV) is char-
acterized by an alteration of genital tract flora such that
the predominant bacteria are no longer lactobacilli, but
instead consist of polymicrobial communities of multiple
genera of gram positive and gram negative organisms [3].
Gardnerella vaginalis,  Prevotella  sp.,Bacteroides  sp.,  Pepto-
streptococcus sp., Mycoplasma hominis and Mobiluncus sp. as
well as other recently described bacteria are commonly
found in BV [2,3]. Lactobacilli, usually L. iners, are also
frequently present in BV, but make up a relatively small
proportion of the total flora [2,4]. BV has been noted to
be the most prevalent vaginal disorder in adult women
worldwide with the frequency depending on the group
that is studied [5]. BV is found in 24% to 37% of women
attending STD clinics but seen at lower rates in women
that are not sexually active.
BV is associated with an increased risk of infections by
HIV and some other organisms as discussed below, as well
as with increased risk of preterm birth, which is a leading
cause of infant death in the United States [6-8]. Treatment
of BV can reduce preterm birth in high risk cases [7,9]. BV
is also associated with miscarriage and pelvic inflamma-
tory disease [10-12].
Diagnosis of BV is commonly made by examination of
four criteria: vaginal fluid pH (BV results in a pH >4.5);
presence of clue cells (bacteria-coated epithelial cells); a
homogenous discharge; and production of an amine odor
when KOH is added to vaginal fluid [13]. Gram stains of
vaginal fluid can also aid in diagnosis of BV [14].
Oral or intravaginal antibiotic treatment with metronida-
zole or clindamycin cures BV in most women, but BV can
resolve spontaneously in nearly a third of subjects [15-
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18]. However, BV recurs in a significant fraction of treated
women.
In vivo studies of the effects of BV on HIV susceptibility and 
expression
Several cross-sectional studies performed in Thailand
[19], Uganda [20], and Malawi [21,22] showed that
women with BV had an increased incidence of HIV infec-
tion. While suggestive, these studies do not prove a cause
and effect relationship between BV and HIV infection.
However, a prospective study in Kenya [23] showed that
the presence of BV and the absence of lactobacilli or
absence of hydrogen peroxide-producing lactobacilli
upon examination were all significantly associated with
acquisition of HIV infection at follow-up.
There is also evidence, some of it through cross-sectional
studies, that the presence of BV increases the risk of infec-
tion with several other sexually transmitted infections
(STI), including herpes simplex virus type 2 (HSV-2), gon-
orrhea, Trichomonas vaginalis and Chlamydia trachomatis
[23-25]. All of these STI have been suggested to increase
susceptibility of women to sexual transmission of HIV
[26], and so BV may both directly increase HIV suscepti-
bility and indirectly increase it by increasing the number
of women with these other STI.
While the above studies suggest that BV can influence sus-
ceptibility of women to HIV infection, other recent studies
suggest that BV increases expression of HIV in the lower
genital tract of women that are already infected with HIV.
Thus, the levels of HIV, as assessed by HIV RNA, and the
detection frequency of HIV in the genital tract are signifi-
cantly higher in the genital tract of women with BV when
compared to women without BV [27,28]. HIV levels were
inversely correlated with levels of lactobacilli but posi-
tively correlated with Mycoplasma hominis [27]. An addi-
tional study showed that women with lower levels of
vaginal lactobacilli had higher genital tract HIV [29].
A number of mechanisms have been suggested that could
account for the increase in susceptibility to HIV and/or
increased expression of HIV in the genital tract (Table 1)
[26,30]. These include decreased levels of hydrogen per-
oxide-producing lactobacilli, production by BV flora of
enzymes (e.g. mucinases) that degrade protective mecha-
nisms such as mucous, or production by BV flora of stim-
ulatory substances that increase influx of target cells, HIV
expression or infection of cells (see below). In fact, BV is
associated with increased levels of pro-inflammatory
cytokines such as IL-1β and IL-8 [Reviewed in [31]]. IL-1β
can induce the production of other pro-inflammatory
cytokines, and IL-8 is known to recruit immune cells, thus
possibly increasing the number of cellular targets for HIV
infection [32].
In vitro studies of the relationship between BV and HIV
A number of in vitro studies show that genital tract fluids
from women with BV are highly stimulatory for immune
cells and can up-regulate expression of HIV. Thus, incuba-
tion of the chronically-HIV-infected monocytic cell line
U1 with genital fluid from women with BV substantially
increased HIV expression [33-36]. In contrast, genital
fluid collected from women without BV did not induce
HIV expression. HIV expression was also induced in T cell
lines and in peripheral blood mononuclear cells by geni-
tal fluids from women with BV [35,37]. The substances in
genital fluids that stimulated HIV expression in cells were
found to function through activation of NF-kB [37].
Bacteria from BV have also been tested for their ability to
stimulate HIV expression in cells. Gardnerella vaginalis, the
bacterium most frequently isolated in BV, significantly
induced HIV expression in U1 cells [38,39]. Lysozyme
treatment reduced U1 activation suggesting a cell wall
component of G. vaginalis was involved in stimulation of
the U1 cells. Anaerobes Peptostreptococcus asaccharolyticus
and Prevotella bivia also stimulated HIV expression [40] as
did non-anaerobic bacteria Mycoplasma hominis and Strep-
tococcus [39]. In contrast, other bacteria found in genital
samples including Bacteroides ureolyticus, Peptostreptococcus
anaerobius, and Lactobacillus acidophilus did not stimulate
HIV expression [40].
Taken together, many of the above studies suggested that
the HIV-stimulatory activity in genital fluids acted
through Toll-like receptors (TLR). For example, genital
fluids stimulated HIV expression through the NF-kB path-
way [41], and stimulation of cells through TLR is well doc-
umented to activate NF-kB [42]. Also, many of the ligands
for TLR are bacterial products [42] and BV mucosal fluids
would be expected to contain such products. A recent
study using the 293 cell line modified to express either
TLR2, TLR4 or control cells expressing no functional TLR,
directly determined whether mucosal fluids from women
with BV stimulated cells through TLR [41]. The results
showed that genital fluids from women with BV stimu-
lated cells predominantly through TLR2, while surpris-
ingly there was relatively little stimulation through TLR4.
In contrast, fluids from women without BV stimulated
Table 1: Possible mechanisms of bacterial vaginosis effects on 
HIV transmission and HIV replication
Increased vaginal pH
Decreased levels of hydrogen peroxide-producing lactobacilli
Production by BV flora of enzymes or substances that inhibit 
anti-HIV immunity
Increased influx of cells susceptible to HIV infection
Increased HIV expression and/or infectionAIDS Research and Therapy 2007, 4:25 http://www.aidsrestherapy.com/content/4/1/25
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cells relatively little through either TLR2 or TLR4. Further,
the TLR2-positive cells supported higher levels of expres-
sion of the HIV promoter when exposed to genital secre-
tions from women with BV, suggesting that HIV-infected
cells in the genital tract might express higher levels of HIV
during episodes of BV. Other studies showed that genital
tract fluid from women with BV can stimulate lym-
phocytes and other cells to express higher levels of TLR4
and TNF-α [43].
Dendritic cells (DC), cells important for antigen process-
ing and presentation to the immune system, are found in
the lower genital tract and are known to express both
TLR2 and TLR4. DC are suggested to be one of the first
cells that take up HIV during sexual transmission [44,45].
DC are also potent antigen presenting cells whose func-
tion would be important for vaccination against a number
of mucosal pathogens, including HIV. We have investi-
gated the hypothesis that genital tract secretions from
women with BV might substantially affect either DC anti-
gen presenting function or DC uptake and infection by
HIV. We observed that secretions from women with BV
potently stimulate secretion of IL-12 by monocyte-derived
dendritic (MDDC) (Figure 1) [46]. Genital fluid from
women with BV also increased MDDC secretion of IL-23
and p40 and upregulated cell surface HLA-DR, CD40 and
CD83. Further, BV fluids decreased MDDC endocytic abil-
ity (a marker of stimulation and maturation of DC) and
increased proliferation of T cells in an allogeneic MLR
with MDDC as the antigen presenting cells [46]. Genital
fluids from women without BV had much lower or no
stimulatory activity for MDDC. These studies suggest that
BV may substantially affect local DC antigen presenting
function in women.
Since the above studies showed that BV genital secretions
potently stimulate DC, we hypothesized that this stimula-
tion might increase infection of DC or enhance the ability
of DC to transfer HIV to T cells. However, our studies to
date do not show BV enhancing HIV infection of DC (Fig.
2) or transfer of HIV by DC to T cells (Fig. 3). In fact, BV
genital secretions appear to suppress HIV transfer to T cells
(Fig. 3). While our studies currently do not support a role
for direct effects of BV genital secretions on DC in enhanc-
ing HIV transmission, these findings do not rule out the
possibility that BV promotes HIV transmission by altering
DC function or trafficking in vivo.
Conclusion
While it has become evident that BV has effects on HIV
transmission, HIV genital tract levels and HIV expression
in vitro, further work is needed to identify the mecha-
nisms responsible for these effects. For example, ques-
tions remain regarding the direct contribution of bacterial
flora versus indirect mechanisms through immune cells,
immune mediators such as cytokines or other mediators.
Effect of Bacterial Vaginosis on HIV infection of MDDC Figure 2
Effect of Bacterial Vaginosis on HIV infection of MDDC. 
MDDC were produced and treated with either Medium 
alone, BV CVL, Normal CVL or LPS for 48 hr as described in 
the Figure 1 legend. Treated MDDC were incubated with 
HIV-1Bal for 24 hr. DNA was then isolated from the MDDC 
and analyzed for HIV DNA copies by real time PCR. Bars 
represent mean + standard error.
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Bacterial Vaginosis induces IL-12p70 production by Dendritic  Cells Figure 1
Bacterial Vaginosis induces IL-12p70 production by Dendritic 
Cells. Monocyte-derived dendritic cells (MDDC) were pro-
duced from monocytes isolated from the blood of normal 
donors using standard methods [46]. MDDC were incubated 
for 48 hours with either culture medium alone (Medium), 
lipopolysaccharide at 1 µg/ml (LPS), or genital tract secre-
tions collected by cervicalvaginal lavage from women with BV 
(BV CVL) or normal flora (Normal CVL). The BV CVL and 
Normal CVL were pools of equal amounts of CVL from 15 
and 14 women respectively. Status of CVL donors was deter-
mined by gram stain. Supernatants were harvested and ana-
lyzed for IL-12p70 by ELISA.
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New in vitro experimental systems or animal models are
needed to help elucidate these mechanisms and are likely
to lead to increased understanding of ways to prevent the
spread of the HIV epidemic.
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Effect of Bacterial Vaginosis on HIV transfer from MDDC to  T cells Figure 3
Effect of Bacterial Vaginosis on HIV transfer from MDDC to 
T cells. MDDC were produced and treated as described in 
the Figure 2 legend and then exposed to HIV-Bal for 2 hours. 
Free virus was removed by washing and MDDC were incu-
bated with PHA stimulated PBMC. Five days later superna-
tants were harvested analyzed for p24 production by ELISA. 
Bars represent mean + standard error.
Medium LPS BV Normal AZT
0
20000
40000
60000
80000
100000
120000
140000
p
2
4
 
p
g
/
m
lPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
AIDS Research and Therapy 2007, 4:25 http://www.aidsrestherapy.com/content/4/1/25
Page 5 of 5
(page number not for citation purposes)
33. Cohn JA, Hashemi FB, Camarca M, Kong F, Xu J, Beckner SK, Kovacs
AA, Reichelderfer PS, Spear GT: HIV-inducing factor in cervicov-
aginal secretions is associated with bacterial vaginosis in
HIV-1-infected women.  J Acquir Immune Defic Syndr 2005,
39:340-346.
34. Olinger GG, Hashemi FB, Sha BE, Spear GT: Association of indica-
tors of bacterial vaginosis with a female genital tract factor
that induces expression of HIV-1.  Aids 1999, 13:1905-1912.
35. Spear GT, al-Harthi L, Sha B, Saarloos MN, Hayden M, Massad LS,
Benson C, Roebuck KA, Glick NR, Landay A: A potent activator of
HIV-1 replication is present in the genital tract of a subset of
HIV-1-infected and uninfected women.  Aids 1997,
11:1319-1326.
36. Zariffard MR, Sha BE, Wang QJ, Chen HY, Bremer J, Cohen MH,
Spear GT: Relationship of U1 cell HIV-stimulatory activity to
bacterial vaginosis and HIV genital tract virus load.  AIDS Res
Hum Retroviruses 2005, 21:945-948.
37. Al-Harthi L, Spear GT, Hashemi FB, Landay A, Sha BE, Roebuck KA:
A human immunodeficiency virus (HIV)-inducing factor
from the female genital tract activates HIV-1 gene expres-
sion through the kappaB enhancer.  J Infect Dis 1998,
178:1343-1351.
38. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT: Activation of
human immunodeficiency virus type 1 expression by Gard-
nerella vaginalis.  J Infect Dis 1999, 179:924-930.
39. Al-Harthi L, Roebuck KA, Olinger GG, Landay A, Sha BE, Hashemi FB,
Spear GT: Bacterial vaginosis-associated microflora isolated
from the female genital tract activates HIV-1 expression.  J
Acquir Immune Defic Syndr 1999, 21:194-202.
40. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT: Induc-
tion of HIV-1 Expression by Anaerobes Associated With
Bacterial Vaginosis.  J Infect Dis 2000, 181:1574-1580.
41. Mares D, Simoes JA, Novak RM, Spear GT: TLR2-mediated cell
stimulation in bacterial vaginosis.  J Reprod Immunol 2007.
42. Carmody RJ, Chen YH: Nuclear factor-kappaB: activation and
regulation during toll-like receptor signaling.  Cell Mol Immunol
2007, 4:31-41.
43. Zariffard MR, Novak RM, Lurain N, Sha BE, Graham P, Spear GT:
Induction of tumor necrosis factor-alpha secretion and toll-
like receptor 2 and 4 mRNA expression by genital mucosal
fluids from women with bacterial vaginosis.  J Infect Dis 2005,
191:1913-1921.
44. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB: Viral piracy: HIV-
1 targets dendritic cells for transmission.  Curr HIV Res 2006,
4:169-176.
45. Morrow G, Vachot L, Vagenas P, Robbiani M: Current concepts of
HIV transmission.  Curr HIV/AIDS Rep 2007, 4:29-35.
46. St John EP, Martinson J, Simoes JA, Landay AL, Spear GT: Dendritic
cell activation and maturation induced by mucosal fluid from
women with bacterial vaginosis.  Clin Immunol 2007, 125:95-102.